Trial Profile

An Open-Label, Phase 1b Study to Evaluate Safety, Tolerability & Preliminary Activity of the CTPS1 Inhibitor STP938 in Adult Subjects With High Risk Essential Thrombocythaemia Who Are Resistant to or Intolerant of Hydroxycarbamide Therapy

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 14 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

15 Oct 2025 According to a Step Pharma media release, the company announced the completion of a 38 million euro Series C financing round. These funds will enable company complete all ongoing phase 1 studies and further derisk dencatistat as the company enter phase 2.
02 Sep 2025 According to a Step Pharma media release, today announced that the first participant has been dosed with dencatistat in a phase 1b clinical trial for essential thrombocythaemia. This trial is being conducted at 12 sites across France and the UK.
09 Jul 2025 Status changed from not yet recruiting to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com